For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $35.97 in the prior trading day, Procept BioRobotics Corp (NASDAQ: PRCT) closed at $35.24, down -2.03%. In other words, the price has decreased by -$2.03 from its previous closing price. On the day, 1.27 million shares were traded. PRCT stock price reached its highest trading level at $36.5 during the session, while it also had its lowest trading level at $34.53.
Ratios:
Our goal is to gain a better understanding of PRCT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.86 and its Current Ratio is at 9.20. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.20.
On July 09, 2025, Stephens started tracking the stock assigning a Overweight rating and target price of $70.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 13 ’25 when MOLL FREDERIC H bought 20,000 shares for $39.26 per share. The transaction valued at 785,138 led to the insider holds 863,159 shares of the business.
Desai Antal Rohit sold 25,000 shares of PRCT for $1,597,711 on Jun 10 ’25. The Director now owns 64,363 shares after completing the transaction at $63.91 per share. On Jun 11 ’25, another insider, Desai Antal Rohit, who serves as the Director of the company, sold 25,000 shares for $63.38 each. As a result, the insider received 1,584,525 and left with 39,363 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRCT now has a Market Capitalization of 1960610560 and an Enterprise Value of 1737260544. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.13 while its Price-to-Book (P/B) ratio in mrq is 5.08. Its current Enterprise Value per Revenue stands at 6.318 whereas that against EBITDA is -20.22.
Stock Price History:
The Beta on a monthly basis for PRCT is 0.99, which has changed by -0.5237838 over the last 52 weeks, in comparison to a change of 0.1719923 over the same period for the S&P500. Over the past 52 weeks, PRCT has reached a high of $103.81, while it has fallen to a 52-week low of $34.01. The 50-Day Moving Average of the stock is -12.79%, while the 200-Day Moving Average is calculated to be -38.66%.
Shares Statistics:
The stock has traded on average 1.16M shares per day over the past 3-months and 1002870 shares per day over the last 10 days, according to various share statistics. A total of 55.58M shares are outstanding, with a floating share count of 52.65M. Insiders hold about 5.37% of the company’s shares, while institutions hold 96.37% stake in the company. Shares short for PRCT as of 1757894400 were 8145600 with a Short Ratio of 7.02, compared to 1755216000 on 8067967. Therefore, it implies a Short% of Shares Outstanding of 8145600 and a Short% of Float of 17.349999999999998.
Earnings Estimates
The company has 9.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.23 and low estimates of -$0.28.
Analysts are recommending an EPS of between -$1.45 and -$1.51 for the fiscal current year, implying an average EPS of -$1.49. EPS for the following year is -$0.94, with 9.0 analysts recommending between -$0.41 and -$1.3.
Revenue Estimates
11 analysts predict $80.78M in revenue for. The current quarter. It ranges from a high estimate of $82.05M to a low estimate of $79.63M. As of. The current estimate, Procept BioRobotics Corp’s year-ago sales were $58.37MFor the next quarter, 11 analysts are estimating revenue of $96.43M. There is a high estimate of $97.37M for the next quarter, whereas the lowest estimate is $95.37M.
A total of 12 analysts have provided revenue estimates for PRCT’s current fiscal year. The highest revenue estimate was $337.31M, while the lowest revenue estimate was $325.35M, resulting in an average revenue estimate of $326.53M. In the same quarter a year ago, actual revenue was $224.5MBased on 12 analysts’ estimates, the company’s revenue will be $426.85M in the next fiscal year. The high estimate is $433.5M and the low estimate is $416.1M.
